Canadian Pharmacare Report Urges Mandatory Substitution
Executive Summary
Recommendations by Canada’s advisory council implementing national pharmacare include mandatory generic substitution and also mechanisms of biosimilar substitution.
You may also be interested in...
Industry Pact Aligns Canadian Prices To International Levels
An agreement between industry and authorities in effect from April last year is already having a major effect in ensuring Canadian generics prices are similar to those in other developed markets, an official report shows.
ASBM Hits Back At British Columbia Switching Scheme
Originator-backed lobbying group the Alliance for Safe Biologic Medicines has raised concerns over a biosimilar switching policy recently unveiled by the Canadian province of British Columbia.
CGPA Points To Lower Prices In Canada
Generics prices in Canada have seen the steepest decline of all OECD countries, the CGPA has highlighted following the release of the latest PMPRB data.